Biogen Idec sales and marketing update

Biogen Idec launched Fampyra fampridine in Ireland to improve walking ability in patients with multiple sclerosis (MS). Fampyra is not available for reimbursement through any of Ireland's Health Service Executive's payment schemes. Biogen Idec declined to disclose pricing information. The sustained-release formulation of 4-aminopyridine (4-AP) has conditional approval in the EU. The product is approved in the U.S. as Ampyra dalfampridine. ...